TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02466334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of normal saline over 20 mins
Study: NCT00206596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily via subcutaneous injection for up 22 weeks
Study: NCT03046082
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation of antibiotic types given to patients with pneumonia.
Study: NCT01265667
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT01265667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT01705002
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
Study: NCT02630316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered four times daily
Study: NCT00585312
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib, 16 mg/kg/day, for 5 years
Study: NCT00585312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masked, placebo comparator
Study: NCT00964106
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine dosed at 100 mg as probe for CYP1A2 pathway
Study: NCT00964106
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed at 40 mg, probe for CYP2C9 pathway
Study: NCT00964106
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed at 10 mg, probe drug for OATP1B1 pathway
Study: NCT03045822
Drug: Bioimpedance analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00575380
Drug: Vigamox Eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop three times a day for seven days
Study: NCT00931996
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
Study: NCT00384306
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01613794
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg od
Study: NCT01071850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00574067
Drug: Counseling +OTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
Study: NCT02291367
Drug: Cymbalta®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg capsule of Eli Lilly and Company
Study: NCT01474187
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625mg/m2,bid,d1-5,qw
Study: NCT05917691
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database).
Study: NCT01514123
Drug: VGX-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGX-100 will be administered by IV infusion once every week
Study: NCT03062839
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 5 mg taken 30 minutes before bed time
Study: NCT04476186
Drug: KOH 10 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for local application
Study: NCT02487082
Drug: Melatonin and Donepezil
Normalized name: donepezil and memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
Study: NCT02812654
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 75mg/m2 (cycle 1,2 and 3)
Study: NCT00429624
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02159287
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 unit per hour continuous intravenous infusion of heparin sodium
Study: NCT00496028
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04108832
Drug: TCM OA2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usage: 3g twice daily
Study: NCT04108832
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage: 3g twice daily
Study: NCT02218307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01859026
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as outlined in study arms.
Study: NCT00638833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills
Study: NCT02438696
Drug: BI 1060469, iFF, Test
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02438696
Drug: BI 1060469, TF2, Test
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02438696
Drug: BI 1060469, TF1, Reference
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00893451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice daily
Study: NCT00442546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00095862
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01668823
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo photodynamic therapy with HPPH
Study: NCT02856087
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion
Study: NCT01263886
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT03558035
Drug: Induction CT+ CRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
Study: NCT04219358
Drug: Vehicle Gel Base
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water.
Study: NCT04219358
Drug: Lip sunscreen 30 Sun Protector Factor (SPF)
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
Study: NCT01530308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dosage of 1mg twice-daily at 12am and 8 pm.
Study: NCT03458143
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conscious sedation in TCI-mode
Study: NCT01806610
Drug: BPS804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose BPS804 administration.
Study: NCT01806610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose placebo administration.
Study: NCT00130234
Drug: Xolair® (Omalizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02426541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
Study: NCT00040690
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00040690
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00040690
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00040690
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00745134
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01428089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01198249
Drug: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
Study: NCT03868111
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Study: NCT03868111
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Study: NCT00472953
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Study: NCT00865449
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
Study: NCT00865449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given daily for 6 months to Peritoneal Dialysis Patients
Study: NCT00930241
Drug: Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advagraf® (one daily dose of Tacrolimus)
Study: NCT00930241
Drug: Prograf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf® (two daily doses of Tacrolimus)
Study: NCT02397213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
Study: NCT04403399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
Study: NCT00172068
Drug: Zoledronic acid + Calcium/Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01769365
Drug: 7-day quadruple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
Study: NCT01769365
Drug: 10-day sequential therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
Study: NCT01769365
Drug: 7-day standard triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
Study: NCT01011725
Drug: MK 0773
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
Study: NCT01011725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet b.i.d for 12 weeks
Study: NCT04542694
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.
Study: NCT02672540
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-hour infusion of Normal Saline and Day 1 and Day 2
Study: NCT00392457
Drug: gonadotropin releasing hormone (GnRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
Study: NCT02295813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006371
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01363011
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
Study: NCT01363011
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV 800 mg tablet administered orally once daily
Study: NCT01363011
Drug: NRTI
Normalized name: Nucleoside Reverse Transcriptase Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
Study: NCT03653026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT01955512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02156154
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03490916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo
Study: NCT02971722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/bottle
Study: NCT00003396
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01563458
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
Study: NCT01270490
Drug: Interferon-gamma, Recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 50 mcg/m2 to be administered three times per week during two weeks
Study: NCT00625326
Drug: 50 µg/g Calcipotriene Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg/g Calcipotriene Ointment
Study: NCT00625326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02575339
Drug: MLN0128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
Study: NCT02575339
Drug: MLN0128 (RP2D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly.
Study: NCT01473147
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 u bid sc.
Study: NCT03527680
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily one capsule of placebo
Study: NCT00111956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00935831
Drug: GSK1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg, 150mg
Study: NCT00935831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04397289
Drug: Heparin and Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
Study: NCT03756883
Drug: Placebo Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active content
Study: NCT04523246
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline, inactive control.
Study: NCT02614833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
Study: NCT02741154
Drug: induction with aromataze inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole 2.5mg once daily start in the first day of menses for 5days
Study: NCT02741154
Drug: HMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
Study: NCT00760786
Drug: Intensive lipid lowering plus Omega3-fatty acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
Study: NCT00760786
Drug: Moderate lipid lowering plus Omega3-fatty acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
Study: NCT00760786
Drug: Intensive lipid lowering plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 40mg qd
Study: NCT00760786
Drug: Moderate lipid lowering plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10mg qd
Study: NCT01483625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01228227
Drug: ROSUVASTATIN 40 mg
Normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: reload of rosuvastatin 40 mg before the procedure
Study: NCT00271024
Drug: Placebo (for Naltrexone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Naltrexone tablet
Study: NCT00432055
Drug: placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04170413
Drug: CeVUS
Normalized name: Cervus elaphus horn oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast enhanced voiding urosonography
Study: NCT03566238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to active drug (A4250).
Study: NCT05667948
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: different treatments based on the molecular analysis
Study: NCT04227041
Drug: Pyrotinib in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pyrotinib in combination with capecitabine
Study: NCT01104428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Study: NCT01104428
Drug: ziying granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Study: NCT00003862
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003862
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04030663
Drug: xlyocaine
Normalized name: Alocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Study: NCT01832402
Drug: Fentanyl Pectin Nasal Spray
Normalized name: fentanyl Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
Study: NCT01832402
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
Study: NCT04812574
Drug: Hypertonic (10%) saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periurethral hypertonic saline (10%)
Study: NCT03206151
Drug: CMAB009
Approvals — FDA: no, EMA: no, PMDA: no
Description: for injection only
Study: NCT00577148
Drug: Placebo (for Rimonabant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT01588535
Drug: benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
Study: NCT01588535
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo solution, five drops in affected ear canal each hour as needed
Study: NCT02087917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.